Plain-English translation of NCT07205328 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help people recover better after an acute ischemic stroke. The medication is designed to protect brain cells and reduce damage from the stroke. Researchers believe this treatment, given alongside standard care, might help people regain more function and independence in the months after their stroke.
Ischemic strokes happen when blood flow to the brain is blocked, and brain cells can be damaged or die. While there are some existing treatments, doctors are looking for new ways to protect the brain and help patients recover better function after a stroke.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive standard stroke care plus either the new medication or a placebo, given as an intravenous infusion twice daily for 14 consecutive days. You will be randomly assigned to receive one of three doses of the medication or placebo—neither you nor your doctors will initially know which you're receiving. The study will track your recovery using standard stroke assessment scales at 14 days and 3 months after your stroke to see if the medication helps improve your outcomes.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
China